IDWeek 2026: BNT163 poised to fulfil a substantial unmet need for genital herpes
BioNTech’s BNT163 has the potential to be a first-in-class prophylactic, for an indication with substantial unmet need.
BioNTech’s BNT163 has the potential to be a first-in-class prophylactic, for an indication with substantial unmet need.